* Stoke Therapeutics Inc STOK.OQ reported a quarterly
adjusted
loss of 46 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -69 cents. The mean expectation of
nine analysts for the quarter was for a loss of 56 cents per
share. Wall Street expected results to range from -65 cents
to -45 cents per share.
* Revenue rose 294.7% to $4.83 million from a year ago;
analysts
expected $3.26 million.
* Stoke Therapeutics Inc's reported EPS for the quarter was
a loss
of 46 cents.
* The company reported a quarterly loss of $25.7 million.
* Stoke Therapeutics Inc shares had risen by 5.3% this
quarter and
gained 170.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 2% in
the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Stoke
Therapeutics Inc is $21.00
This summary was machine generated from LSEG data August 7 at
01:26 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.56 -0.46 Beat
Mar. 31 2024 -0.61 -0.57 Beat
Dec. 31 2023 -0.63 -0.60 Beat
Sep. 30 2023 -0.63 -0.55 Beat